SCHEMBL20239208

SCHEMBL20239208

CS(=O)(=O)Nc1ccc(Oc2cc(CNc3ncc(Cl)cn3)nc(N)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.53
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 4/20 0.41
ALDH1A1 P00352 1/20 0.41
PGR P06401 1/20 0.40
PTK2 Q05397 1/20 0.39
GRIN1 Q05586 4/20 0.39
GRIN2B Q13224 4/20 0.39
KCNH2 Q12809 1/20 0.39
MET P08581 1/20 0.38
NPC1 O15118 3/20 0.37
CHEK2 O96017 1/20 0.37
LTA4H P09960 1/20 0.36
AR P10275 1/20 0.36
HPGD P15428 1/20 0.36
KIF11 P52732 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239338 0.89 SMN1; SMN2 (0.46) DGAT2MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL20239246 0.89 DGAT2 (0.50) DGAT2SMN1; SMN2RAB9APGRPTK2
SCHEMBL20239259 0.87 DGAT2 (0.49) DGAT2SMN1; SMN2RAB9APGRPTK2
SCHEMBL20239226 0.85 DGAT2 (0.53) DGAT2MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL20239321 0.84 DGAT2 (0.46) DGAT2MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL20239204 0.84 DGAT2 (0.69) DGAT2MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL20239203 0.84 DGAT2 (0.59) DGAT2MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL20239200 0.82 DGAT2 (0.76) DGAT2GRIN1GRIN2BKCNH2LTA4H
SCHEMBL20239364 0.81 DGAT2 (0.62) DGAT2MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL20239255 0.81 DGAT2 (0.53) DGAT2MEN1KMT2ASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885MEN1 4508/4885KMT2A 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.